Corleen M. Roche
Corleen M. Roche's purchase track record
Corleen M. Roche has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/29/2024 | CGON | $38K | +17.1% | -15.3% | +10.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
CG Oncology appoints Isabel Kalefonos as Chief Commercial Officer. CG Oncology announced the appointment of Isabel Kalefonos as its new chief commercial officer. The hire adds experienced biopharmaceutical leadership as the company prepares for a possible bladder cancer product launch. The addition may strengthen the commercial strategy ahead of upcoming market activities.
Transaction History
| IOVA | ▲ Buy | Option Exercise | 49,995 | $0 | 8/6/2026 | View on chart |
| IOVA | ▼ Sell | Tax Withholding | 21,238 | $132K | 8/6/2026 | View on chart |
| CGON | ▲ Buy | Open Market | 2,000 | $38K | 1/29/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Iovance Biotherapeutics sees analyst target raise and whale activity
Recent reports show large investors were active in IOVA shares, indicating heightened interest. Baird kept a neutral stance but lifted its price target to $11, above its prior level. The Q2 2026 earnings call highlighted ongoing clinical progress, which aligns with the analyst’s revised outlook. The stock is near the upper end of its 52‑week range.
Iovance Biotherapeutics sees analyst target raise and whale activity. Recent reports show large investors were active in IOVA shares, indicating heightened interest. Baird kept a neutral stance but lifted its price target to $11, above its prior level. The Q2 2026 earnings call highlighted ongoing clinical progress, which aligns with the analyst’s revised outlook. The stock is near the upper end of its 52‑week range.